OXFORD, United Kingdom, March 19 (Bernama-GLOBE NEWSWIRE) — Refeyn, developer of pioneering mass photometry technology, announces the launch of MyMass™ mass photometer (MyMassMP), a compact instrument designed to answer a critical research question: Is the sample good enough for further analysis?
Structure-based drug design and AI-driven therapeutic development are transforming how new medicines are discovered, but depend on high-quality samples. Structural and biophysical workflows, such as cryo-EM, native mass spectrometry (MS), bio-layer interferometry (BLI), and surface plasmon resonance (SPR), are time-consuming and costly, and poor sample quality remains one of the main reasons they fail. MyMassMP gives researchers a fast, accurate assessment of purity, homogeneity, and oligomerization state in solution before committing to resource-intensive experiments.